Roflumilast (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Roflumilast" in French language version.

refsWebsite

Global rank French rank

3sciencedirect.com

149^th place

80^th place

1,735^th place

168^th place

1atsjournals.org

low place

4,703^rd place

low place

2,283^rd place

1ersjournals.com

low place

7,855^th place

2,374^th place

298^th place

low place

8,434^th place

low place

7,368^th place

atsjournals.org

(en) Beghe B, Rabe KF, Fabbri LM, « Phosphodiesterase-4 inhibitor therapy for lung diseases » Am J Respir Crit Care Med, 2013;188:271–278.

chestnet.org

journal.publications.chestnet.org

(en) White WB, Cooke GE, Kowey PR et al. « Cardiovascular safety in patients receiving roflumilast for the treatment of COPD » Chest, 2013;144:758–765.

endocrine.org

press.endocrine.org

(en) Wouters EF, Bredenbroker D, Teichmann P et al. « Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus » J Clin Endocrinol Metab, 2012;97: e1720–e1725.

ersjournals.com

erj.ersjournals.com

(en) Bateman ED, Rabe KF, Calverley PM et al. « Roflumilast with long-acting β2 agonists for COPD: influence of exacerbation history » Eur Respir J, 2011;38:553–560.

nejm.org

Lebwohl MG, Papp KA, Stein Gold L et al. Trial of roflumilast cream for chronic plaque ssoriasis, N Engl J Med, 2020;383:229-239

prescrire.org

« Roflumilast (Daxas°) - un médicament à écarter des soins », sur prescrire.org (consulté le 13 décembre 2022)

qmul.ac.uk

chem.qmul.ac.uk

Masse molaire calculée d’après « Atomic weights of the elements 2007 », sur www.chem.qmul.ac.uk.

sciencedirect.com

(en) Calverley PM, Rabe KB, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ, « Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials » Lancet, 2009;374:685–694.
(en) Fabbri LM, Calverley PM, Izquierdo-Alonso JL et al. « Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials » Lancet, 2009;374:695–703.
(en) Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF, « Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial » Lancet, 2015;385:857–866.